Spyre Therapeutics enters the post-earnings stretch with an unusual alignment: analysts racing to raise targets, short sellers steadily trimming positions, and the stock up 21% over the past month to $104.94.
The Street's reaction to this week's results was immediate and one-directional. Three firms raised price targets on August 5 alone — Wells Fargo lifted to $115, while Guggenheim and Wedbush both moved to $130, leaving the consensus mean at $118. That follows a Mizuho raise to $120 in mid-July and Deutsche Bank's earlier move to $135. The lone dissent came from Wolfe Research, which downgraded to Peer Perform on July 28 without issuing a target. The direction of travel is clear: bulls see $115–$135 as the right range, with the bear case centered on slow SKYWAY-RD enrollment and competitive pressure from Merck and Roche's rival TL1A programs. Against a current price of $104.94, the consensus implies roughly 13% further upside — meaningful but not aggressive for a clinical-stage biotech with this momentum profile.
Short positioning tells a story of measured retreat rather than panic covering. Short interest has drifted lower for the past month, now at roughly 16% of the free float — still elevated for a biotech name, but down from above 17% in early July and off the peaks that coincided with the mid-July period of uncertainty. More telling is the lending market: availability has loosened dramatically, jumping to 922% this week from around 542% a week ago, meaning there are now more than nine shares available to borrow for every one already shorted. Borrowing costs are negligible at 0.44% annually, down 6% on the week. This is not a market where shorts are under pressure — borrow is cheap and plentiful, and the ORTEX short score has eased from 66.6 three weeks ago to 63.2 now, consistent with shorts slowly reducing rather than building. The options market adds a small layer of caution: the put/call ratio has crept to 1.28, modestly above its 20-day average of 1.21, suggesting some hedging has appeared alongside the rally — but the z-score of 1.3 is nowhere near an alarm level.
Institutional ownership reinforces the constructive tone. Fidelity (FMR) holds 13.4% of shares and added to its position in Q2. BlackRock added roughly 307,000 shares in the same period. Specialist healthcare funds including Perceptive Advisors and RTW Investments collectively hold another 9%-plus of the company. The counterweight is a cluster of insider selling in late June and early July: CEO Cameron Turtle, CFO Scott Burrows, and Chief Medical Officer Sheldon Sloan all sold shares on July 1, collectively around $2.5 million at prices near $87–$88. More substantially, Fairmount Funds Management — a board-level investor — sold nearly 4.7 million shares on June 23 for roughly $400 million. The 90-day net insider figure is technically positive in share terms due to that transaction's structure, but the direction of executive selling warrants attention, particularly given the stock has since risen more than 20%.
The two earnings prints with reaction data present a mixed picture. After the May 27 quarterly release, the stock fell 2.1% the next day and was essentially flat five days later. The May 8 release produced a 4.6% next-day gain and a 2.5% five-day gain. The next earnings event is scheduled for November 6, leaving the next several months as a pipeline catalyst window rather than an earnings-driven period — clinical readouts from the SKYWAY trials will likely determine whether the short retreat accelerates or reverses.
What to watch next is whether the combination of loosening borrow availability and rising analyst targets brings new short sellers into the stock at current levels, or whether the continued drift lower in short interest signals that the bear thesis is losing adherents ahead of the next clinical data window.
See the live data behind this article on ORTEX.
Open SYRE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
